SEARCH

SEARCH BY CITATION

References

  • 1
    Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59 (2): 732–737.
  • 2
    Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KMH. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196202.
  • 3
    Ascher N, Sutherland DER, Payne W et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44 (3): 376381.
  • 4
    Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15 (2): 8994.
  • 5
    Roth D, Milgrom M, Esquenazi V, Fuller L, Burke G, Miller J. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47 (2): 278281.
  • 6
    Homel P, Maursky V, Markell MS et al. Diabetes mellitus after renal transplantation: as deleterious as non- transplant-associated diabetes? Transplantation 1998; 65 (3): 380384.
  • 7
    Jawad F, Rizvi SA. Posttransplant diabetes mellitus in live-related renal transplantation. Transplant Proc 2000; 32 (7): 1888.
  • 8
    Davis R, Daskalakis P, Friedman EA et al. Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplant Proc 1991; 23 (1 Pajt 2): 12491250.
  • 9
    Hathaway DK, Tolley EA, Blakely ML, Winsett RP, Gaber AO. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993; 7 (4): 330338.
  • 10
    Stenstrom J, Leivestad T, Egeland T et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64 (7): 979983.
  • 11
    Von Kiparski A, Frei D, Uhlschmid G, Largiader F, Binswanger U.Post-transplant diabetes mellitus in renal allograft recipients: a matched-pair control study. Nephrol Dial Transplant 1990; 5 (3): 220225.
  • 12
    Rao M, Jacob CK, Shastry JC. Post-renal transplant diabetes mellitus – a retrospective study. Nephrol Dial Transplant 1992; 7 (10): 10391042.
  • 13
    Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996; 61 (10): 14751478.
  • 14
    Al-Uzri A, Stablein DM, Cohn RA. Posttransplant diabetes mellitus in pediatric renal transplant recipients. a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 72 (6): 10201024.
  • 15
    Aikawa I, Fukuda M, Yasumura T et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 12 (1): 1117.
  • 16
    Tzakis A, McCauley J, Jordan M et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23 (6): 31693170.
  • 17
    Isoniemi H.Renal allograft immunosuppression V. Glucose intolerance occurring in different immunosuppressive treatments. Clin Transplantation 1991; 5: 268272.
  • 18
    Ponticelli C, Civati G, Tarantino A et al. Randomized study with cyclosporine in kidney transplantation: 10-year follow-up. J Am Soc Nephrol 1996; 7: 792797.
  • 19
    Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61 (11): 15761581.
  • 20
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63 (7): 977983.
  • 21
    Besse T, Grabensee B, Klein B et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64 (3): 436443.
  • 22
    Vivas C, Marsh JW, McCauley J et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67 (3): 411415.
  • 23
    Calne R, Kreis H, Lang P et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67 (7): 10361042.
  • 24
    Halloran P, Stegall M, Hardy Met al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 695: 834841.
  • 25
    Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69 (5): 875880.
  • 26
    Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14 (6): 270277.
  • 27
    Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25 (583): 592.
  • 28
    Hammon RE, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes prevention program research group. New Engl J Med 2002; 346: 393403.
  • 29
    Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21 (6): 11351139.
  • 30
    Perret G, Richardet JP, Raffoux C et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996; 20 (6–7): 544548.
  • 31
    Knobler H, Stagnaro-Green A, Wallenstein S, Schwajtz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26 (1): 3033.
  • 32
    Qian K, Alexander GJ, Xu L et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29 (2): 328333.
  • 33
    Wanless IR, Hemming AW, Croxford R et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32 (1): 8790.
  • 34
    Karavelioglu D, Baysal C, Özdemir N et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 2000; 32 (3): 561562.
  • 35
    Toffolo G, Breim D, Lormann J et al. Interferon-alpha improves glucose tolerance in diabetic and non- diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes 1999; 107 (6): 343349.
  • 36
    Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72 (6): 10661072.